Healthcare Industry News:  ViroPharma 

Biopharmaceuticals Personnel

 News Release - January 3, 2008

ViroPharma Augments Senior Management

Company Appoints Thomas Doyle Vice President, Strategic Initiatives and Promotes Peter Wolf to Vice President, General Counsel and Secretary of the Board of Directors

EXTON, Pa., Jan. 3 (HSMN NewsFeed) -- ViroPharma Incorporated (Nasdaq: VPHM ) announced today that effective, January 1, 2008, Thomas F. Doyle has been appointed as vice president, strategic initiatives and J. Peter Wolf has been promoted to vice president, general counsel and secretary of the Board of Directors.

Mr. Doyle will oversee strategic planning efforts at ViroPharma including expanding exclusivity of the current product portfolio, and assist in business development activities. He will also continue leading the efforts in ViroPharma's ongoing discussions with the U.S. Food & Drug Administration regarding the company's continuing efforts to assure the safety of patients afflicted by C. difficile infection. Prior to his appointment, Mr. Doyle served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.

"Tom has been a great leader for ViroPharma for well over a decade and during that time has helped navigate the company through times of both prosperity and difficulty," commented Michel de Rosen, ViroPharma's president and chief executive officer. "Tom continues to represent well the ViroPharma values of teamwork, people, quality and courage; he has great passion for ViroPharma and his integrity is second to none. I look forward to continuing to work closely with Tom in this critical new role for ViroPharma's future."

Mr. Wolf will be responsible for the oversight of ViroPharma's legal department and serve as corporate secretary. Mr. Wolf has been ViroPharma's Associate General Counsel since April 2004. Immediately prior to joining ViroPharma, Mr. Wolf was an attorney at Pepper Hamilton LLP. Mr. Wolf received his J.D. from George Washington National Law Center. Prior to attending George Washington, Mr. Wolf received his B.A. in International Relations from the University of Delaware.

"Since joining ViroPharma in 2004, Pete has demonstrated great teamwork, sound judgment and excellent customer focus," commented de Rosen. "He has a seemingly limitless capacity for work. We are very fortunate at ViroPharma to have a highly qualified individual such as Pete already in the organization to assume and expand the role of general counsel."

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin® approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.ViroPharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at www.ViroPharma.com.


Source: ViroPharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.